Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 23, 2024

SELL
$48.48 - $57.85 $1.39 Million - $1.66 Million
-28,697 Reduced 82.05%
6,278 $322,000
Q3 2023

Nov 03, 2023

BUY
$57.89 - $64.73 $69,178 - $77,352
1,195 Added 3.54%
34,975 $2.03 Million
Q2 2023

Jul 19, 2023

SELL
$63.71 - $70.74 $52,560 - $58,360
-825 Reduced 2.38%
33,780 $2.16 Million
Q1 2023

Apr 24, 2023

BUY
$65.71 - $74.53 $441,834 - $501,139
6,724 Added 24.12%
34,605 $2.4 Million
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $333,086 - $394,421
4,864 Added 21.13%
27,881 $2.01 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $2,160 - $1.28 Million
16,620 Added 259.81%
23,017 $1.64 Million
Q2 2022

Aug 11, 2022

BUY
$72.62 - $79.98 $10,529 - $11,597
145 Added 2.32%
6,397 $492,000
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $12,111 - $14,522
197 Added 3.25%
6,252 $457,000
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $3,003 - $3,501
56 Added 0.93%
6,055 $378,000
Q3 2021

Nov 08, 2021

SELL
$59.17 - $69.31 $3,491 - $4,089
-59 Reduced 0.97%
5,999 $355,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $19,996 - $21,776
-323 Reduced 5.06%
6,058 $411,000
Q1 2021

Apr 28, 2021

BUY
$59.34 - $66.74 $3,263 - $3,670
55 Added 0.87%
6,381 $402,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $57,566 - $65,233
997 Added 18.71%
6,326 $392,000
Q3 2020

Nov 04, 2020

BUY
$57.43 - $63.64 $9,131 - $10,118
159 Added 3.08%
5,329 $321,000
Q2 2020

Aug 05, 2020

BUY
$54.82 - $64.09 $274 - $320
5 Added 0.1%
5,170 $304,000
Q1 2020

Apr 27, 2020

SELL
$46.4 - $67.43 $12,017 - $17,464
-259 Reduced 4.78%
5,165 $287,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $266,915 - $348,166
5,424 New
5,424 $348,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Regent Peak Wealth Advisors LLC Portfolio

Follow Regent Peak Wealth Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regent Peak Wealth Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regent Peak Wealth Advisors LLC with notifications on news.